Drug & Device Pipeline News
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Trials Authorized | |||
| Aquestive Therapeutics | AQST-109 | Severe allergic reactions | IND approved by the FDA |
| RedCloud Bio | H002 | EGFR-positive nonsmall-cell lung cancer | IND approved by the FDA |
| Sorrento Therapeutics | STI-9199 (Covishield) | COVID-19 | IND approved by the FDA |
| Harbour BioMed | HBM7008 | Solid tumors | Approval for a phase 1 trial granted by Australia’s regulatory authority |
| InnoCare Pharma | Orelabrutinib | Neuromyelitis optica spectrum disorder | Approval for a phase 2 trial granted by China’s regulatory authority |
| Trials Initiated | |||
| ProJenX | PRO-101 | Amyotrophic lateral sclerosis | Initiation of phase 1 trial |
| Oncocross | OC514 | Sarcopenia | Initiation of phase 1 trial in Australia |
| Elpiscience | ES104 | Colorectal cancer | Initiation of phase 1/2 trial in China |
| Genprex | Reqorsa plus Tagrisso | Nonsmall-cell lung cancer | Initiation of phase 1/2 trial |
| Intellia Therapeutics | NTLA-5001 | Acute myeloid leukemia | Initiation of phase 1/2 trial |
| Bold Therapeutics | BOLD-100 | Advanced gastrointestinal cancers | Initiation of phase 2 portion of phase 1b/2 trial |
| Transcenta | TST001 | Biliary tract cancer | Initiation of phase 2a trial in China |
| Xalud Therapeutics | XT-150 | Facet joint osteoarthritis pain | Initiation of phase 2a trial |
| Actuate Therapeutics | Elraglusib plus retifanlimab | Advanced pancreatic cancer | Initiation of phase 2 trial |
| Aramis Biosciences | A197 | Dry eye disease | Initiation of phase 2 trial |
| CatalYm | CTL-002 (visugromab) | Solid tumors | Initiation of phase 2 trial |
| Kazia Therapeutics | Paxalisib | Glioblastoma | Initiation of phase 2 trial |
| Kintor Pharmaceutical | KX-826 (pyrilutamide) | Male androgenetic alopecia | Initiation of phase 2 trial |
| Lynk Pharmaceuticals | LNK01001 | Atopic dermatitis | Initiation of phase 2 trial |
| ALX Oncology Eli Lilly |
Evorpacept plus ramucirumab | HER2-positive gastric cancer or gastroesophageal junction cancer | Initiation of phase 2/3 trial |
| Seelos Therapeutics | SLS-005 | Amyotrophic lateral sclerosis | Initiation of phase 2/3 trial |
| Lyra Therapeutics | LYR-210 | Chronic rhinosinusitis | Initiation of phase 3 trial |
| NewAmsterdam Pharma | Obicetrapib | Atherosclerotic cardiovascular disease | Initiation of phase 3 trial |
| Approvals | |||
| Boehringer Ingelheim | Jardiance (empagliflozin) | All types of heart failure | Approved by the FDA for expanded indication |
| CTI BioPharma | Vonjo (pacritinib) | Myelofibrosis and thrombocytopenia | Accelerated approval granted by the FDA |
| Legend Biotech | Carvykti (ciltacabtagene autoleucel) | Relapsed or refractory multiple myeloma | Approved by the FDA |
| Kaléo | Naloxone auto-injector | Exposure to ultrapotent weaponized opioids | Approved by the FDA |
| Medicago GlaxoSmithKline |
Covifenz COVID-19 vaccine | COVID-19 | Approved in Canada |
Upcoming Events
-
12Apr
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May
